05 September 2019
Visiongain has launched a new pharma report Sleep Apnea Devices Market Report 2019-2029: By Diagnostic Devices (Polysomnography Devices (PSG), Pulse Oximeters, Actigraphy Devices), by Therapeutic Devices (Positive Airway Pressure (PAP) Devices, Oxygen Devices, Oral Appliances, Adaptive Servo Ventilation (ASV) Devices, Masks and Accessories) and Geography.
Global Sleep Apnea Devices Market is anticipated to grow on account of rising geriatric population, increased awareness, growing pool of undiagnosed sleep apnea patients and growing disease diagnosis rates. The global sleep apnea devices market is anticipated to grow at a lucrative CAGR of 6.7% and anticipated to reach USD 9.27 Billion by 2029.
Sleep apnea is a severe sleep disorder that happens when the breathing of a person during sleep is disrupted. People with untreated sleep apnea stop breathing constantly during their sleep.
The most prevalent type of apnea induced by airway blockage is obstructive sleep apnea. Patients must undergo diagnostic exams and use therapeutic therapy equipment to prevent this. In a sleep center or a home sleep apnea test, OSA is most frequently diagnosed with either polysomnography (PSG). OSA risk factors include obesity, aging, family history, and abnormalities of the facial or upper airways.
Demand for OSA diagnosis and therapy has seen a fast rise in recent years, caused by exponential development in sleep apnea incidence, increased awareness, reimbursement accessibility, and increased patient adherence. According to the OHE-Office of Health Economics, OSA diagnosis, awareness and therapy can save up to USD 31 million of Nation Health Service. It is also noted that if everyone with mild to serious OSA were handled, it would be possible to prevent approximately 40,000 road accidents each year. Also rising number of OSA cases coupled with growing awareness about various treatments options is fueling the growth of the global market.
North America maintains a majority share of the market, and growth is ascribed to increased incidence of sleep disorders and increased government and non-governmental organizations initiatives to raise awareness of sleep disorders and sleep hygiene. Several government agencies run awareness programs to educate individuals and doctors about good sleeping habits. Asia Pacific region is expected to experience the highest growth in terms of CAGR over the forecast period owing to the development of healthcare infrastructure in this region, combined with increased awareness among the population regarding associated risks of sleep apnea.
Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations and launching new products in order to strengthen their position in the global single-cell genomics market. Companies are also expanding their R&D, distribution, and management facilities in order to expand their business and to hold a competitive edge in the market. For instance, ResMed (US) introduced its first top-of-head nasal CPAP mask, AirFit N30i, across the US in 2019, with a freshly constructed nasal cradle cushion that sits just below the wearer's nose.
The comprehensive market report features companies such as Airing, Apnex Medical, BMC Medical, Braebon Medical, Carefusion Corporation, Compumedics, Contec Medical, Curative Medical Inc., Drive Devilbiss Healthcare, Fisher & Paykel Healthcare, Huanan Medical, Inspire Medical Systems, Invacare Corporation, Invicta Medical, Inc., Itamar Medical Ltd., Koninklijke Philips N.V., Löwenstein Medical, Medtronic, Natus Medical, Inc., Nihon Kohden, Nonin Medical, Novasom, Nukute, Nyxoah, Oventus, ResMed, Sefam, SomnoMed, Weinmann Medical Devices GmbH, and Whole You among other prominent players.
Also the research study offers market estimation and forecast for the period ranging 2019–2029 for global markets such as North America, Latin America, Western Europe, Eastern Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Nordic, Benelux, Russia, Poland, India, Japan, China, Australia, ASEAN, GCC, South Africa and North Africa.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
29 July 2021
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
21 July 2021
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
20 July 2021
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.